Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer

Bogdanos, Dimitrios P.; Gkoutzourelas, Athanasios; Papadopoulos, Vasilios; Liaskos, Christos; Patrikiou, Eleni; Tsigalou, Christina; Saratziotis, Athanasios; Hajiioannou, Jiannis; Scheper, Thomas; Meyer, Wolfgang; Sakkas, Lazaros I.; Papandreou, Christos N.

doi:10.1016/j.cca.2021.07.006

Cited by 16 publications

(20 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recently, anti-TRIM21 antibodies have been detected in patients with ovarian cancer, the presence of which correlated with better patient survival. Analysis showed these antibodies differed in epitope profile to anti-TRIM21 antibodies detected in SLE and SS, although why this is the case remains to be discovered (133).…”

Section: Trim21 and Dysregulation Of Cellular Homeostasismentioning

confidence: 89%

TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease

2021

View full text Add to dashboard Cite

TRIM21 (Ro52/SSA1) is an E3 ubiquitin ligase with key roles in immune host defence, signal transduction, and possibly cell cycle regulation. It is also an autoantibody target in Sjögren’s syndrome, systemic lupus erythematosus, and other rheumatic autoimmune diseases. Here, we summarise the structure and function of this enzyme, its roles in innate immunity, adaptive immunity and cellular homeostasis, the pathogenesis of autoimmunity against TRIM21, and the potential impacts of autoantibodies to this intracellular protein.

show abstract

Section: Trim21 and Dysregulation Of Cellular Homeostasismentioning

confidence: 89%

TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease

2021

View full text Add to dashboard Cite

show abstract

“…The rate of anti-Ro52 antibody positivity is about 12% in the general population, and ranges from 5.9% to 30% in cancers ( 11 , 28 ). However, the presence of anti-Ro52 antibody may not indicate an increased risk of cancer ( 29 ).…”

Section: Discussionmentioning

confidence: 99%

“…Anti-Ro52 (TRIM21) antibody, one member of the ANA profile, is regarded to be associated with many autoimmune diseases, especially Sjogren’s syndrome, systemic lupus erythematosus, and systemic sclerosis ( 10 ). The prevalence of anti-Ro52 antibody varies in malignant diseases ( 11 , 12 ). Previous studies suggested that anti-Ro52 positivity was correlated with better overall survival in patients with ovarian cancer ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

Tang

Geng

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe present retrospective cohort study evaluated the safety and efficacy of PD-1/PD-L1 inhibitors in patients with preexisting autoantibodies. Patients who received PD-1/PD-L1 inhibitors in the Department of Medical Oncology, Peking Union Medical College Hospital between November 2017 and August 2021 were reviewed.Results67 (37.9%) of the 177 patients, 27 (20.3%) of the 133 patients, and 16 (11.0%) of 146 patients who received PD-1/PD-L1 inhibitors were positive for ANA, anti-Ro52, and antithyroid antibodies, respectively. Preexisting ANA and anti-Ro52 antibody were not associated with the increased risk of immune-related adverse events (irAEs), while thyroid dysfunction was more frequent in patients with positive antithyroid antibody (75.0% versus 13.8%, p < 0.001). The median progression-free survival (PFS, 13.1 versus 7.0 months, p = 0.015) was significantly longer in the ANA-positive patients, while the median overall survival (OS, 14.5 versus 21.8 months, p = 0.67) did not differ significantly between the ANA-positive and ANA-negative groups. Moreover, the preexisting anti-Ro52 and antithyroid antibodies were not significantly associated with PFS and OS.ConclusionsThe presence of ANA and anti-Ro52 antibody were not associated with a higher risk of irAEs, whereas patients positive for antithyroid antibody should monitor closely immune-related thyroid dysfunction. Preexisting ANA might be a predictor of longer PFS, while anti-Ro52 and antithyroid antibodies had no significant effect on survival outcomes in patients receiving PD-1/PD-L1 inhibitors therapy.

show abstract

“…Our retrospective analysis found that anti-Ro52 (27, 21.09%) is the most common target antibody in the ANA spectrum for RR positive cases. That may be because anti-Ro52 is a frequent autoantibody in AIDs, and is also described in some non-autoimmune disorders and a wide range of inflammatory disorders including malignant diseases, as well as in healthy controls ( 44 ). It was reported that there was a close relationship between anti-RR and anti-histone ( 30 ), but we have not confirmed the correlation between RR pattern and specific antibodies.…”

Section: Discussionmentioning

confidence: 99%

The clinical value of indirect immunofluorescence for screening anti-rods and rings antibodies: A retrospective study of two centers in China

Meng

Yang²,

Li³

et al. 2022

Front. Immunol.

View full text Add to dashboard Cite

ObjectiveTo investigate the distribution and clinical significance of the rods and rings (RR) pattern in various diseases.MethodsA total of 169,891 patients in Peking Union Medical College Hospital (PUMCH) and 29,458 patients in Inner Mongolia People’s Hospital (IMPH) from January 2018 to December 2020 were included, and the results of ANA (antinuclear antibodies) and special antibodies were analyzed retrospectively.ResultsThe positive rates of ANA and RR patterns were 34.84%, 0.16% in PUMCH, and 44.73%, 0.23% in IMPH. Anti-RR antibodies mainly appear in adults (≥ 41 years), mostly of low or medium fluorescence titers. Isolated RR patterns were mostly presented (60.30% and 69.12%, respectively), and the RR pattern mixed with the speckled pattern was most commonly observed among patients having two or more patterns. The RR pattern existed in a variety of diseases including hepatitis C, AIDs, pulmonary diseases, nephropathy diseases, and even healthy people. The highest prevalence of the RR pattern was observed in hepatic diseases, such as hepatic dysfunction (0.79%), hepatic cirrhosis (1.05%), PBC (0.85%), and AIH (0.65%), etc. The positive rate of specific antibodies in RR pattern cases was 31.25%, and anti-Ro52 (27, 20.61%) was the most common target antibody.ConclusionThe RR pattern had a low prevalence in ANAs test samples and varied in different nationalities and regions. Except for hepatitis C, it could be observed in AIDs, pulmonary diseases, nephropathy, other hepatic diseases, and even healthy people, but the positive rate was slightly higher in hepatic diseases. Its mechanism of action and clinical relevance still need clarification.

show abstract

Anti-Ro52 antibody is highly prevalent and a marker of better prognosis in patients with ovarian cancer

Cited by 16 publications

References 40 publications

TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease

TRIM21/Ro52 - Roles in Innate Immunity and Autoimmune Disease

Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

The clinical value of indirect immunofluorescence for screening anti-rods and rings antibodies: A retrospective study of two centers in China

Contact Info

Product

Resources

About